F 0755
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Some
Provide pharmaceutical services to meet the needs of each resident and employ or obtain the services of a
licensed pharmacist.
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on
clinical record review and staff interview it was determined that the facility failed to ensure that the
pharmacy provided medications timely for two of three residents reviewed (Resident R1 and R2).
Findings include:
Review of Resident R1's clinical record revealed Resident R1 was admitted [DATE], with diagnoses of but
not limited to Hematuria (blood in the urine), acute angle-closure Glaucoma (condition that causes pressure
to go up quickly in the eye and block the drainage system), CVA (cerebral vascular accident - stroke),
hypertension (high blood pressure), and Depression.
Review of Resident R1's physician's admission orders included an order for Dorzolamide HCl Ophthalmic
Solution 2%, instill 1 drop in both eyes two times a day related to acute angle-closure glaucoma, bilateral.
Review of the February 2024 Medication Administration Record (MAR) revealed that Dorzolamide was not
administered January 18-23, 2024 for a total of ten times.
Review of progress notes of January 19, January 20, and January 21, 2024, revealed awaiting delivery and
delivery is pending for eye drops. Review of progress note of January 22, 2024, revealed pharmacy was
called and assured eye drop would be delivered late tonight. Review of progress note of January 23, 2024,
revealed med [eye drops] not available at this time. Pharmacy said they will be here tonites run. Review of
progress note of January 23, 2024, revealed staff spoke with pharmacy at 3:30 p.m. regarding the eye
drops and pharmacy indicated they may need authorization from the Director of Nursing (DON) for new
bottle to be delivered. Review of progress note of January 23, 2024, revealed family brought in eye drops
which were administered.
Review of Resident R2's clinical record revealed that Resident R2 was admitted [DATE], with diagnoses of
but not limited to hypothyroidism (underactive thyroid), multiple sclerosis (disease affect the central nervous
system), hypertension, type II diabetes(disease that occurs when blood sugar is too high) and respiratory
failure (syndrome in which the respiratory system fails).
Review of physician admission orders included orders for, but not limited to, Fluticasone-Salmeterol
Inhalation Aerosol Powder Breath Activated 250-50 MCG/ACT 1 puff inhale orally two times a day related to
respiratory failure, Ascorbic Acid Oral Tablet 500 MG (milligrams) Give 1 tablet by mouth two times a day for
vitamin deficiency, Amlodipe Besylate Oral Tablet 2.5 MG Give 1 tablet by mouth one time a day related to
essential (primary) hypertension, Aspirin Low Dose Oral Tablet Chewable 81
(continued on next page)
Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other
safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the
date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date
these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER
REPRESENTATIVE'S SIGNATURE
TITLE
(X6) DATE
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Facility ID:
If continuation sheet
Page 1 of 2
Event ID:
396083
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
396083
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
02/08/2024
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Sterling Health Care and Rehab Center
318 South Orange Street
Media, PA 19063
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0755
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Some
MG Give 1 tablet by mouth one time a day for prophylaxis, : Brexpiprazole Oral Tablet 2 MG Give 1 tablet by
mouth one time a day related to depression, : Benztropine Mesylate Oral Tablet 2 MG Give 1 tablet by
mouth three times a day for tremors, Diclofenac Potassium Oral Capsule 25 MG Give 1 capsule by mouth
two times a day related to low back pain, DULoxetine HCl Oral Capsule Delayed Release Particles 30 mg
Give 1 capsule by mouth one time a day related to depression administer together with Duloxetine 60 mg
for total of 90 mg, Famotidine Oral Tablet 20 mg Give 1 tablet by mouth one time a day for GERD
(gastroesophageal reflux disease - digestive disorder), levetiracetam Oral Tablet 750 MG Give 1 tablet by
mouth two times a day related to metabolic encephalopathy (condition in which brain function is disturbed
due to different diseases or toxins in the body), Gabapentin Oral Tablet 800 MG Give 1 tablet by mouth four
times a day related to low back pain, Omega-3 Fish Oil Oral Capsule 1000 MG, Omeprazole Oral Capsule
Delayed Release 40 MG Give 1 capsule by mouth one time a day for heartburn, Myrbetriq Oral Tablet
Extended Release 24 Hour 25 MG Give 1 tablet by mouth one time a day related to chronic obstructive
pyelonephritis (inflammation of the kidney, Vitamin E Oral Capsule 180 MG, Torsemide Oral Tablet 20 MG
Give 1 tablet by mouth one time a day related to chronic obstructive pyelonephritis,Vitamin D3 Oral Capsule
1.25 MG (50000 UT) Give 2 capsule by mouth one time a day for vitamin D deficiency, Lidocaine HCl
External Cream 3 % Apply to affected area topically every day and evening shift for pain, and Insulin
Glargine-yfgn 100 UNIT/ML Solution pen-injector Inject 25 unit subcutaneously at bedtime related to type 2
diabetes mellitus.
Review of Resident's R2's January 2024 MAR revealed that the above medications were not administered
as ordered.
Review of progress note of January 23, 2024, revealed medications were not administered and were
waiting on delivery from pharmacy.
Interview with the Director of Nursing (DON) on February 8, 2024, at 1:20 p.m. confirmed that Resident R1
did not receive the eye drops that were ordered on admission. The facility was unable to determine if they
were delivered from the pharmacy and the pharmacy required reauthorization to supply the eye drops. The
DON also confirmed that the family brought in eye drops. The DON indicated the Resident R2 was a late
admission at approximately 11:30 p.m. and did not meet the pharmacy's cut-off time for delivery of
medications.
28 Pa. Code 211.12(d)(1)(3)(5) Nursing services
Previously cited 10/27/23
28 Pa. Code: 211.9 (a)(1) Pharmacy services.
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
396083
If continuation sheet
Page 2 of 2